Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.
Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine addresses the improvements that are needed in the future of closed-loop systems for diabetes treatment.
Transcript (slightly modified)
What are the opportunities for improvement with the current closed-loop systems and how can they be addressed?
I know the system is approved but this is not the end of the closed-loop system research, it’s just the beginning actually, we are just starting.
We have a hybrid closed-loop system. It still requires users input for meals, you still have to count carbs, and in the background its adjusting insulin delivery. For future systems, our ultimate goal is the full automated system. It's on autopilot; you don’t have to worry about it, and it will deliver insulin, make adjustments, and in a way you can forget about diabetes—that’s the goal. To get there, we need better devices, maybe even smaller devices, better connection—so phone or other devices—and personalized medicine, like fine-tuning that insulin dose adjustments just for you.
I think we can do a lot more in that field and investigate closed-loop systems in populations like younger children and elderly so we can customize treatments for them. When you have a fast system, when you have a system that’s optimizing insulin delivery every 5 minutes, you need better insulins to keep up with that. It’s like you can’t think of using those old phone and internet connections with your iPads now. It might work, but you’re not going to get the best results with those old, slow internet connections. Like that, we need faster methods to accelerate insulin action so it can keep up with the system.
I think there is so much more, we are going to learn a lot, and this is going to also be a learning experience. Once we have more experience, we’ll have more questions and more ways to improve the system. But, the ultimate goal is just to have a system that is small, easy to use, and takes away all of the burden and fear of hypoglycemia so you can enjoy your life and the algorithm and device will do the work for you. So, that’s hopefully going to be the system of the near future.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More